Merck & Co raises outlook as Keytruda offsets Lagevrio decline

27 April 2023

A fall in sales of the COVID-19 treatment Lagevrio (molnupiravir) led revenue at Merck & Co (NYSE: MRK) to fall by 9% to $14.49 billion in the first quarter of 2023.

This figure was still better than Wall Street had anticipated. Analysts, on average, had expected sales of $13.8 billion, according to Refinitiv data. Excluding Lagevrio, growth was 11%, driven by a 20% rise in sales of the immuno-oncology blockbuster Keytruda (pembrolizumab), which brought in $5.8 billion in the quarter.

The US pharma giant said it earned $1.40 a share in the quarter, compared with $2.14 a share last year. Analysts, on average, had expected $1.32 a share.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK